Company: DNLI
Filing Date: 2025-12-04
Form Type: 8-K
Source: 0001714899-25-000208
Chunk: 1

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-04
Form: 8-K
Item: Item 1.01
Chunk 1
---
 and commercialization activities; and other information relating to the transaction between Royalty Pharma and Denali. Actual results are subject to risks and uncertainties and may differ materially from those projected or implied in these forward-looking statements as a result of these risks and uncertainties, including but not limited to: the risk that the transaction may not close in a timely manner or at all; risks related to obtaining the requisite regulatory approvals; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement; and other risks, including those described in Denali’s Annual Report on Form 10-K and Quarterly Report filed on Form 10-Q filed with the SEC on February 27, 2025, and November 6, 2025, respectively, and Denali’s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali’s expectations, except as required by law.

Item 9.01 Financial Statements and Exhibits.